The Canada Research Chair in Biomaterials and Endovascular Implants, which was launched in 2008 and renewed in 2013, aims to design and create new coatings, biomaterials, and implants to improve the treatment of pathologies, in particular, cardiovascular pathologies. The research team led by Sophie Lerouge (Laboratoire de Biomatériaux endovasculaires, LBEV) is especially interested in endovascular treatments, which are less invasive than conventional surgery. The team is working closely with physicians to address clinical needs. Our approach consists in studying the causes of failure of current therapies using explant analysis data and animal models that replicate clinical complications and, subsequently, designing and assessing more effective medical devices.

One of the strategies developed is to develop bioactive coatings produced by plasma method and chemical grafting of active biomolecules, in order to optimize the biological response around the implants such as stents, covered stents, metallic coils or vascular prostheses.

The second line of research is to develop and characterize injectable biomaterials for the minimally invasive treatment of pathologies. The chair has developed radiopaque embolic agents for embolizing blood vessels, to treat or to prevent frequent blood leakage during treatment of aneurysms. A radiopaque hydrogel combining both embolizing and sclerosing properties is also ongoing technology transfer. The chair also develops hydrogels with good mechanical resistance and biocompatibility for cell therapy and tissue engineering. Their use in combination with stem cells or immune cells is under investigation for various applications.

CRC-Biomaterials-Folder (PDF)